3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow Purdue Pharma, Canada: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) PRC-063 oral capsules, Placebo oral capsules - ADHD | Phase 3 | Completed | Purdue Pharma, Canada | 288 | 2018-08-21 | 2021-07-26 |
| PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD PRC-063 oral capsules, Placebo oral capsules - ADHD | Phase 3 | Completed | Purdue Pharma, Canada | 156 | 2017-05-01 | 2019-11-05 |
| The Efficacy and Safety of PRC-063 in Adult ADHD Patients Placebo, PRC-063 25 mg, PRC-063 45 mg - ADHD | Phase 3 | Completed | Rhodes Pharmaceuticals, L.P. | 375 | 2014-04-01 | 2019-05-07 |
Attention Deficit Disorder with Hyperactivity (3)
United States (3) · Canada (1)
Sailaja Bhaskar, PhD (2) · Joseph Reiz (1)